Genprex Inc
Company Profile
Business description
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex’s oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company’s product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.
Contact
3300 Bee Cave Road
Suite 650-227
AustinTX78746
USAT: +1 877 774-4679
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
13
Stocks News & Analysis
stocks
Market too pessimistic about unloved ASX health care share
stocks
Two overvalued ASX shares to avoid
stocks
Materially undervalued ASX tech share
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,899.30 | 6.50 | -0.07% |
| CAC 40 | 8,052.02 | 26.22 | 0.33% |
| DAX 40 | 23,508.87 | 44.24 | 0.19% |
| Dow JONES (US) | 47,112.45 | 664.18 | 1.43% |
| FTSE 100 | 9,629.56 | 20.03 | 0.21% |
| HKSE | 25,928.08 | 33.53 | 0.13% |
| NASDAQ | 23,025.59 | 153.59 | 0.67% |
| Nikkei 225 | 49,559.07 | 899.55 | 1.85% |
| NZX 50 Index | 13,562.01 | 81.58 | 0.61% |
| S&P 500 | 6,765.88 | 60.76 | 0.91% |
| S&P/ASX 200 | 8,606.50 | 9.50 | -0.11% |
| SSE Composite Index | 3,864.18 | 5.84 | -0.15% |